New Paradigms in Hypersensitivity Pneumonitis
Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and...
Ausführliche Beschreibung
Autor*in: |
Ahluwalia, Bineet [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Anmerkung: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
Übergeordnetes Werk: |
Enthalten in: Current respiratory care reports - New York, NY : Springer, 2012, 11(2022), 4 vom: 08. Okt., Seite 116-131 |
---|---|
Übergeordnetes Werk: |
volume:11 ; year:2022 ; number:4 ; day:08 ; month:10 ; pages:116-131 |
Links: |
---|
DOI / URN: |
10.1007/s13665-022-00295-5 |
---|
Katalog-ID: |
SPR048812765 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR048812765 | ||
003 | DE-627 | ||
005 | 20230519110850.0 | ||
007 | cr uuu---uuuuu | ||
008 | 221206s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13665-022-00295-5 |2 doi | |
035 | |a (DE-627)SPR048812765 | ||
035 | |a (SPR)s13665-022-00295-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ahluwalia, Bineet |e verfasserin |4 aut | |
245 | 1 | 0 | |a New Paradigms in Hypersensitivity Pneumonitis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. | ||
650 | 4 | |a Hypersensitivity pneumonitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Diagnosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Treatment |7 (dpeaa)DE-He213 | |
650 | 4 | |a Radiology |7 (dpeaa)DE-He213 | |
700 | 1 | |a Singh, Sheetu |0 (orcid)0000-0003-3888-9856 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current respiratory care reports |d New York, NY : Springer, 2012 |g 11(2022), 4 vom: 08. Okt., Seite 116-131 |w (DE-627)718610954 |w (DE-600)2660484-X |x 2161-332X |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2022 |g number:4 |g day:08 |g month:10 |g pages:116-131 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13665-022-00295-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
951 | |a AR | ||
952 | |d 11 |j 2022 |e 4 |b 08 |c 10 |h 116-131 |
author_variant |
b a ba s s ss |
---|---|
matchkey_str |
article:2161332X:2022----::eprdgsnyesniiiy |
hierarchy_sort_str |
2022 |
publishDate |
2022 |
allfields |
10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131 |
spelling |
10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131 |
allfields_unstemmed |
10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131 |
allfieldsGer |
10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131 |
allfieldsSound |
10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131 |
language |
English |
source |
Enthalten in Current respiratory care reports 11(2022), 4 vom: 08. Okt., Seite 116-131 volume:11 year:2022 number:4 day:08 month:10 pages:116-131 |
sourceStr |
Enthalten in Current respiratory care reports 11(2022), 4 vom: 08. Okt., Seite 116-131 volume:11 year:2022 number:4 day:08 month:10 pages:116-131 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Hypersensitivity pneumonitis Diagnosis Treatment Radiology |
isfreeaccess_bool |
false |
container_title |
Current respiratory care reports |
authorswithroles_txt_mv |
Ahluwalia, Bineet @@aut@@ Singh, Sheetu @@aut@@ |
publishDateDaySort_date |
2022-10-08T00:00:00Z |
hierarchy_top_id |
718610954 |
id |
SPR048812765 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048812765</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221206s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13665-022-00295-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048812765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13665-022-00295-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ahluwalia, Bineet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Paradigms in Hypersensitivity Pneumonitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypersensitivity pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, Sheetu</subfield><subfield code="0">(orcid)0000-0003-3888-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current respiratory care reports</subfield><subfield code="d">New York, NY : Springer, 2012</subfield><subfield code="g">11(2022), 4 vom: 08. Okt., Seite 116-131</subfield><subfield code="w">(DE-627)718610954</subfield><subfield code="w">(DE-600)2660484-X</subfield><subfield code="x">2161-332X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:08</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:116-131</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13665-022-00295-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">08</subfield><subfield code="c">10</subfield><subfield code="h">116-131</subfield></datafield></record></collection>
|
author |
Ahluwalia, Bineet |
spellingShingle |
Ahluwalia, Bineet misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology New Paradigms in Hypersensitivity Pneumonitis |
authorStr |
Ahluwalia, Bineet |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718610954 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
2161-332X |
topic_title |
New Paradigms in Hypersensitivity Pneumonitis Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 |
topic |
misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology |
topic_unstemmed |
misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology |
topic_browse |
misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Current respiratory care reports |
hierarchy_parent_id |
718610954 |
hierarchy_top_title |
Current respiratory care reports |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)718610954 (DE-600)2660484-X |
title |
New Paradigms in Hypersensitivity Pneumonitis |
ctrlnum |
(DE-627)SPR048812765 (SPR)s13665-022-00295-5-e |
title_full |
New Paradigms in Hypersensitivity Pneumonitis |
author_sort |
Ahluwalia, Bineet |
journal |
Current respiratory care reports |
journalStr |
Current respiratory care reports |
lang_code |
eng |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
116 |
author_browse |
Ahluwalia, Bineet Singh, Sheetu |
container_volume |
11 |
format_se |
Elektronische Aufsätze |
author-letter |
Ahluwalia, Bineet |
doi_str_mv |
10.1007/s13665-022-00295-5 |
normlink |
(ORCID)0000-0003-3888-9856 |
normlink_prefix_str_mv |
(orcid)0000-0003-3888-9856 |
title_sort |
new paradigms in hypersensitivity pneumonitis |
title_auth |
New Paradigms in Hypersensitivity Pneumonitis |
abstract |
Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
abstractGer |
Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
abstract_unstemmed |
Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 |
container_issue |
4 |
title_short |
New Paradigms in Hypersensitivity Pneumonitis |
url |
https://dx.doi.org/10.1007/s13665-022-00295-5 |
remote_bool |
true |
author2 |
Singh, Sheetu |
author2Str |
Singh, Sheetu |
ppnlink |
718610954 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s13665-022-00295-5 |
up_date |
2024-07-03T21:37:58.603Z |
_version_ |
1803595471759867904 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048812765</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221206s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13665-022-00295-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048812765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13665-022-00295-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ahluwalia, Bineet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Paradigms in Hypersensitivity Pneumonitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypersensitivity pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, Sheetu</subfield><subfield code="0">(orcid)0000-0003-3888-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current respiratory care reports</subfield><subfield code="d">New York, NY : Springer, 2012</subfield><subfield code="g">11(2022), 4 vom: 08. Okt., Seite 116-131</subfield><subfield code="w">(DE-627)718610954</subfield><subfield code="w">(DE-600)2660484-X</subfield><subfield code="x">2161-332X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:08</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:116-131</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13665-022-00295-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">08</subfield><subfield code="c">10</subfield><subfield code="h">116-131</subfield></datafield></record></collection>
|
score |
7.3996468 |